Q1 Earnings Forecast for NAMS Issued By Leerink Partnrs

NewAmsterdam Pharma (NASDAQ:NAMS) – Equities researchers at Leerink Partnrs issued their Q1 2025 earnings estimates for NewAmsterdam Pharma in a research report issued to clients and investors on Tuesday, December 17th. Leerink Partnrs analyst R. Ruiz expects that the company will post earnings per share of ($0.20) for the quarter. The consensus estimate for NewAmsterdam Pharma’s current full-year earnings is ($1.79) per share. Leerink Partnrs also issued estimates for NewAmsterdam Pharma’s Q2 2025 earnings at ($0.34) EPS, Q3 2025 earnings at ($0.35) EPS, FY2025 earnings at ($1.25) EPS, FY2026 earnings at ($1.15) EPS and FY2027 earnings at ($1.20) EPS.

Several other research analysts have also commented on the company. Piper Sandler reiterated an “overweight” rating and issued a $37.00 target price on shares of NewAmsterdam Pharma in a research report on Monday, September 23rd. Scotiabank boosted their target price on shares of NewAmsterdam Pharma from $35.00 to $47.00 and gave the company a “sector outperform” rating in a research note on Wednesday, December 11th. Needham & Company LLC reissued a “buy” rating and set a $36.00 target price on shares of NewAmsterdam Pharma in a report on Thursday, December 5th. Finally, Royal Bank of Canada reaffirmed an “outperform” rating and issued a $31.00 price target on shares of NewAmsterdam Pharma in a report on Thursday, September 5th. Six analysts have rated the stock with a buy rating, According to MarketBeat, the stock has an average rating of “Buy” and an average target price of $36.20.

NewAmsterdam Pharma Price Performance

Shares of NewAmsterdam Pharma stock opened at $25.50 on Friday. The business has a 50-day moving average price of $21.31 and a 200 day moving average price of $18.95. NewAmsterdam Pharma has a fifty-two week low of $10.50 and a fifty-two week high of $27.29.

Institutional Investors Weigh In On NewAmsterdam Pharma

A number of hedge funds and other institutional investors have recently modified their holdings of NAMS. FMR LLC increased its stake in NewAmsterdam Pharma by 35.6% during the 3rd quarter. FMR LLC now owns 330,412 shares of the company’s stock valued at $5,485,000 after buying an additional 86,712 shares during the period. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC boosted its holdings in shares of NewAmsterdam Pharma by 1,231.0% in the third quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC now owns 239,283 shares of the company’s stock valued at $3,972,000 after acquiring an additional 221,305 shares in the last quarter. abrdn plc boosted its holdings in shares of NewAmsterdam Pharma by 69.8% in the third quarter. abrdn plc now owns 129,060 shares of the company’s stock valued at $2,142,000 after acquiring an additional 53,060 shares in the last quarter. Millennium Management LLC increased its stake in shares of NewAmsterdam Pharma by 23.0% during the second quarter. Millennium Management LLC now owns 1,165,429 shares of the company’s stock valued at $22,388,000 after acquiring an additional 217,902 shares during the period. Finally, Jennison Associates LLC raised its holdings in NewAmsterdam Pharma by 8.9% during the third quarter. Jennison Associates LLC now owns 1,020,278 shares of the company’s stock worth $16,937,000 after purchasing an additional 83,115 shares in the last quarter. 89.89% of the stock is currently owned by institutional investors.

Insider Buying and Selling at NewAmsterdam Pharma

In related news, CAO Louise Frederika Kooij sold 45,000 shares of the firm’s stock in a transaction that occurred on Tuesday, October 1st. The stock was sold at an average price of $15.72, for a total value of $707,400.00. The transaction was disclosed in a legal filing with the SEC, which is available through this link. Also, major shareholder Nap B.V. Forgrowth sold 100,728 shares of the business’s stock in a transaction on Wednesday, December 18th. The stock was sold at an average price of $26.10, for a total value of $2,629,000.80. Following the transaction, the insider now owns 10,908,502 shares of the company’s stock, valued at $284,711,902.20. This trade represents a 0.91 % decrease in their position. The disclosure for this sale can be found here. Over the last three months, insiders have sold 353,542 shares of company stock worth $8,599,328. 19.50% of the stock is owned by insiders.

NewAmsterdam Pharma Company Profile

NewAmsterdam Pharma Company N.V., a late-stage biopharmaceutical company, develops therapies to enhance patient care in populations with metabolic disease. It is developing obicetrapib, an oral low-dose cholesteryl ester transfer protein (CETP) inhibitor, that is in various clinical trials as a monotherapy and a combination therapy with ezetimibe for lowering LDL-C for cardiovascular diseases.